Destiny Pharma’s Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections
Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]
